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In 2019, a new coronavirus (SARS-CoV-2) infecting Humans first identified in Wuhan, China, has caused the worst 
pandemic of the 21st century. This virus infection leads to the clinical symptoms that may range from asymptomatic 
condition to life-threatening illness. The insights from the recent studies suggest that SARS-CoV-2 requires a host enzyme, 
Furin to activate receptor-binding domain (RBD) of its S protein. Upon binding of RBD to host cell membrane-bound 
Angiotensin Convertase Enzyme 2 (ACE2), it facilitates the entry of virus in the host cell. Evidence from the literature also 
suggests that HIF-1α (Hypoxia-inducible factor 1-α) is one of the factors regulating the expression of Furin. In addition, it is 
also well documented that the interior of solid tumours, which grow very fast, leads to the hypoxic tumour 
microenvironment, resulting in overexpression and release of HIF-1α. The SARS-CoV-2 infected patients with severe tissue 
damage and inflammatory injury also suffer from tissue hypoxia. So, we hypothesize that hypoxic condition due to tumour 
microenvironment in cancer patients upregulates the HIF-1α, leading to increased expression of Furin. Upon infection of 
cancer patients with SARS-CoV-2 having increased Furin expression in the cells due to upregulation of HIF-1α, leads to the 
entry of a greater number of SARS-CoV-2 virus in these cells resulting in severe infection. The vicious cycle of the virus 
infection in which virus is more easily invaded into surrounding tissue leads to the involvement of multiple organs and 
ultimately poor prognosis in the disease outcome. Therefore, we suggest evaluating the expression of HIF-1α in SARS-
CoV-2 infections at an early phase of infection particularly in patients with comorbidities like solid malignancies as well as 
patients having signs and symptoms of hypoxia. It is also suggested that continuous monitoring of the SpO2 level and early 
institution of preventive O2 therapy at an early stage in these patients may lead to lesser morbidity as well as mortality in 
COVID-19 patients. 
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Introduction 
COVID-19 
In December 2019, a series of patients with 
symptoms resembling viral pneumonia presented in 
Wuhan, Hubei province, China emerged
1
. Later the 
disease has spread to more than 200 countries 
throughout the world and infected more than eighteen 
million people leading to more than 7,00,000 deaths. 
The whole-genome sequencing and the phylogenetic 
evaluation revealed that the newly emergent virus is 
more closely related to SARS coronavirus
2
. So, the 
novel coronavirus was named severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), and the 
resulting disease termed as COVID-19. 
SARS-CoV-2 disease symptoms resemble SARS-
CoV and Middle East respiratory syndrome coronavirus 
(MERS-CoV). COVID-19 primarily spread through the 
saliva or the discharge from the nose of the patient
3
. 
Coronaviruses belong to the Coronaviridae family. 
It is enveloped, single-stranded, and possess positive-
sense RNA. The total length of the genome is 30 Kb, 
consisting of a 5-terminal noncoding region, an open 
reading box (ORF) 1a/b-coding region, an s region 
encoding the spike glycoprotein (S protein), an 
e region encoding the envelope protein (E protein), an 
m region encoding the membrane protein (M protein), 
an n region encoding the nucleocapsid protein 
(N protein), and a -3-terminal noncoding region
4
. 
Role of Furin in SARS-CoV-2 Infection 
Like all other coronaviruses, SARS-CoV-2 also needs 
its S protein cleaved to facilitate its entry to host cells. 
Unlike SARS-CoV, the S1/S2 site in SARS-CoV-2 
contains multiple arginine residues (multi-basic)
5,6
. 
The presence of polybasic residues at the S1/S2 site 
requires a different cleavage strategy for SARS-CoV-2 
—————— 
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for efficient proteolytic processing in human tissues and 
also confers better cleavability. While a monobasic site 
is sufficient for SARS-CoV to be cleaved by TMPRSS2 
(Transmembrane Serine Protease 2), a multi-basic S1/S2 
site cleavage is essential for efficient SARS-CoV-2 
entry into human lung cells
7
.  
The cleavage of S protein at the S1/S2 cleavage 
site in SARS-CoV-2 is catalysed by a host proprotein 
convertase Furin (Fig. 1), a calcium-dependent 
membrane-bound protease which is expressed 
ubiquitously as a 794 amino acid zymogen that 
undergoes autocatalytic cleavage to become fully 
active. S1 is essential for the attachment to receptor i. e. 
angiotensin-converting enzyme 2 (ACE2) receptors 




ACE2, a type I transmembrane metallocarboxy–
peptidase mainly found attached to the outer surface of 
the lungs, arteries, heart, kidney, and intestines, acts 
as a functional receptor for SARS-CoV-2 S-mediated 
entry into cells (Fig. 1). Increase affinity between  
S1 and hACE2 (human angiotensin-converting 
enzyme 2) may be a key for the efficient transmission 
of SARS-CoV-2 in humans
5
.  
Regulation of Furin by HIF-1α in Cancers 
HIF-1α (Hypoxia-inducible factor 1-), is a subunit 
of a heterodimeric transcription factor hypoxia-inducible 
factor 1-, encoded by the HIF1A gene. Significant 
overexpression of HIF-1α has been reported in most 
solid tumours studied, which include cancers of the 
colon, ovary, breast, prostate, pancreas, kidneys, brain, 
bladder, etc. (Fig. 1)
10
. Increased HIF-1α levels have 
been associated with aggressive tumour progression and 
reported as a predictive and prognostic marker for 
therapy resistance to radiotherapy, chemotherapy. 
Increased mortality in several solid cancers, including 
cervical cancer, non-small-cell lung carcinoma, breast 




In most of the solid tumours, the rate of growth of 
tumour outpaces the neovascularization. As a result, 
there is a relatively hypoxic microenvironment inside 
the tumour. HIF-1α is induced due to this low oxygen 
concentration in the tumour microenvironment. It is 
reported that HIF-1α positively correlated with the 
expression of Furin in the case of solid tumours i. e. 
the expression of Furin is upregulated upon HIF-1α 
stimulation
12




Fig. 1 — Tumour hypoxia induces increased viral load through HIF-1α-Furin mediated pathway. Intratumor hypoxia, a common 
phenomenon in solid tumours, leads to stabilization of HIF-1α, which in turn induce the upregulation of furin. Furin catalyses the 
formation of S1 and S2 fragments in S protein. S2 remains attached to SARS-CoV-2, acts as Receptor Binding Domain (RBD) for ACE2, 
constitutively expressed on epithelial cells of the upper aerodigestive tract, facilitating the increasing entry of the virus into the host cell 




expected to have upregulated expression of Furin. 
Also due to increased Furin expression, it was 
hypothesised that oral cancer patients have a higher 
risk of SARS CoV-2 infection as well as the increased 
severity of the disease (Fig. 1). The plausible 
mechanism behind the Furin upregulation is that  
HIF-1α binds to the hypoxia-responsive elements 
present on the promoter region of Furin
14
. It is also 
reported that hypoxia further favours relocalisation of 
intracellular Furin to the cell surface
15
. On the other 
hand, Furin also positively regulates the HIF-1α in 
squamous carcinoma cells
16
 (Fig. 1).  
 
Hypoxia and Inflammation in COVID-19 
ACE2, which acts as a functional receptor for host-
virus interaction in SARS-CoV-2 infection, is highly 
expressed on the cell surface of many tissues and 
organs including the lungs and the myocardium, hence 
the early involvement of lung and the severity of the 
respiratory syndrome are explained
17,18
. The local 
damage caused by the ARDS (Acute Respiratory 
Distress Syndrome) to the tissue of lungs leads to 
inflammatory changes and thus the inflammation can 
also lead to the hypoxic condition at the site of viral 
infection
19,20
. The tissue damage is also responsible for 
hypoxic conditions that can upregulate HIF-1α which 
in turn upregulate Furin expression
21
. Furin, then 
enhance the process for the SARS-CoV-2entry 
resulting in the severity of the disease. Thus, it suggests 
that the hypoxic microenvironment in COVID-19 
contributes to the disease worsening.  
 
Hypothesis 
As it is evident from the literature that SARS-CoV-2 
requires host enzymes Furin to activate the receptor 
binding domain of its S protein and ACE2 is required as 
the functional binding receptor, facilitating the entry of 
the virus in the host cell. Intra-tumor hypoxic conditions 
in solid tumours like breast cancer, lung cancer etc. 
induce the HIF-1α in tumour and its neighbouring 
tissues that ultimately upregulate proprotein convertase 
Furin expression. Again, at the early stage of infection  
with SARS-CoV-2, there is an insult to the respiratory 
system leading to hypoxic conditions and an increase in 
HIF-1α. Therefore, a hypothesis arises which states that 
COVID-19 infection in patients with solid tumour 
causes the upregulation in HIF-1α. Then HIF-1α 
upregulates the expression of Furin in neighbouring cells 
that further facilitates the entry of SARS-CoV-2 virus in 
neighbouring tissues resulting in the vicious viral cycle 
and more chances of multiple organ involvement in the 
patients. Also, as the cancer patients already have the 
upregulated HIF-1α in the tumour microenvironment. 
The possibility of poor prognosis in the cancer patients 
infected with SARS-CoV-2 is much higher due to pre 
up-regulated HIF-1α.  
 
Discussion 
It has been reported that the infection rate in cancer 
patients due to SARS-CoV-2 was higher than the 
general population, deteriorating conditions, and poor 
outcomes
22
. As it is evident that Furin expression is 
upregulated in cancer patients, So the infection of 
cancer patients with SARS-CoV-2 may result in poor 
prognosis. A serious matter of concern has been 
raised by the oncologists regarding increased chances 
of infection due to the immunocompromised nature of 
the cancer patients due to cancer itself or due to the 
nature of anticancer therapy, making them utmostly 
vulnerable with the very adverse outcome as reported 
by Kuderer et al. by a multicentric study of Cancer 
Consortium (CCC19) registry database
23
.  
Hypoxia is a physiological as well as a pathological 
condition associated with a large number of diseases 
such as in cancer and bacterial and viral infections. The 
expression of protein hypoxia-inducible factor 1-α is 
regulated by the pro-inflammatory cytokines, growth 
factors, and infections. In SARS-COV-2 infection, it 
may be presumed that the viral infection is leading to the 
tissue deprivation of oxygen. In response to oxygen 
deprivation, hypoxia-inducible factor 1-α is stabilized. 
Upon stabilization, it binds to HIF-responsive elements 
(HREs) in the gene promoter region that responds to the 
hypoxic condition
24
. In Cancer, the expression of Furin 
was increased when the HIF-1α expression was induced. 
Thus in SARS-COV-2 infection, the stimulation of  
HIF-1α might be upregulating the Furin expression. 
Hence, leading to the severity of the infection.  
Again, it is a well-documented fact that the Furin 
gene is constitutively expressed. However, the 
regulation of the expression of Furin is yet not well 
explored. But few in vitro studies reported that the 
expression of Furin is upregulated when the 
expression of HIF-1α and SOX9 is upregulated. Thus 
the expression of Furin is not only upregulated by 
HIF-1α
25
. To date, the positive feedback loop 
involving HIF-1α and Furin expression is studied in 
cancer only, to the best of our knowledge. Overall 
solid cancer leads to the hypoxic environment, which 
in turn leads to the activation of HIF-1α. Thus the 
expression of furin is stimulated in response to 
oxygen deprivation, as all three FUR promoters have 
the binding sites for the hypoxia-inducible factor 1-α. 




So if the expression of HIF-1α is induced in SARS-
CoV-2 infection, then it might be possible that HIF-1α 
is stimulating Furin expression.  
Interestingly, there is no study reporting the 
expression level of HIF-1α in tissues or serum of 
COVID-19 patients to substantiate our theory. However, 
there is indirect evidence of a possible increase in  
HIF-1α as many studies have reported hypoxic 
conditions in SARS-CoV-2 infection either due to 
inflammation or viral pneumonia. Moreover, the 
immune response against the viral infection leads to the 
positive regulation of the apoptotic pathway in the 
infected cells. The exaggerated inflammatory response 
often results in tissue damage. The molecular pathways 
involved during the viral infection, mediating the 
increased cell damage and inflammation are the areas of 
active research. But it has been reported that the cell 
death and inflammatory injury, at the site of virus 
infection, can also lead to hypoxia. The hypoxic 
environment also plays the important role in the 
regulation of various genes such as HIF-1α, HIF-2α, 
NF-κB (nuclear factor-kappa B), CREB (cAMP-
response Element-binding Protein), Nrf (NF-E2-related 
factor), STATs (signal transducers and activators  
of transcription)
26
. In case of severe infection of  
SARS-CoV-2, the patients showed tissue damage and 
inflammatory response. So, the hyperinflammatory 
response might results in the hypoxic environment at the 
infected site. There is a possibility that in response to 
SARS-CoV-2, the expression of HIF-1α will be higher 
in COVID-19 patients, due to the hypoxic environment, 
which further results in the upregulation in the 
expression of Furin. Furin plays a key role in the entry of 
the virus into the host cell. Therefore, it might  
be possible that HIF-1α is regulating the entry of  
SARS-CoV-2 into the host cells by regulating the 
expression of Furin. This will result in a vicious cycle 
where the hyper inflammation and tissue damage due to 
viral infection leads to increased expression of HIF-1α, 
which further enhances SARS-CoV-2 entry by 
upregulating the expression of Furin. Therefore, HIF-1 
expression most probably is the key player that 
upregulates the Furin, further increasing the viral entry 
in the neighbouring tissues of COVID-19 patients and 
multiple organ involvement. On the other hand, patients 
with solid tumours already have increased HIF-1α levels 
due to intra-tumour hypoxia. Along with it the 
expression of Furin is also upregulated in cancer 
patients. Thus suggesting that these may be the factors 
that cancer patients are more susceptible to infection due 
to SARS-CoV-2. Thus, in our opinion, early signs of 
even a very small degree of hypoxia may be considered 
an ominous sign in the cancer patients because it can 
predict early involvement of multiple organ involvement 
and ultimately poor prognosis in COVID-19. In the 
patients having hypoxia at earlier stages of infection, an 
earlier institution of O2 as a preventive measure may 
lead to a better outcome in Cancer patients infected with 
SARS-CoV-2. Confirmation of the hypothesis can help 
to improve the prognosis in patients with COVID-19 
infections in normal as well as in cancer patients. Thus, 
targeting HIF-1α can be a plausible way to decrease the 
COVID-19 pathogenesis in cancer patients.  
HIF-1α inhibitors are categorized as direct 
inhibitors and indirect inhibitors. The direct inhibitors 
target HIF-1α whereas the indirect inhibitors target 
the molecules upstream or downstream the HIF-1α 
signalling axis. In SARS-CoV-2 infection, we are 
more interested to specifically target the function of 
HIF-1α so it will be better to use the direct inhibitors. 
The direct inhibitors can be used as a single agent or 
the agent combined with other molecules. 2ME2 
NCD (Panzem), 17-AAG (Tanespimycin), Vorinostat 
(SAHA, Zolinza), EZN-2208 (Pegylated SN-38), 
CRLX101 are some of the drugs targeting HIF-1α. 
These drugs are FDA approved and are in their 
Clinical trials for treating the cancers. So these agents 
may be of potential use to specifically target the  
HIF-1α in SARS-CoV-2 infection
27
.  
However, Furin cannot be targeted to be a potential 
molecule in COVID-19 infection as this is a very 
important proprotein convertase, physiologically 
catalysing a lot of very important molecules to their 
biologically active products e.g. proalbumin, 
proparathyroid hormone, TGFβ, MMPs, β subunit of 
pro-nerve growth factor, von-Wille brand factor etc. 
Thus, targeting Furin may result in loss of 
physiological homeostasis.  
On the contrary, it has been hypothesized in one of 
the studies that HIF-1α is playing the opposite role as 
proposed by ours in the prognosis of SARS-CoV-2 
patients
28
. Though it is the hypothesis stating the 
protective role of HIF-1α in SARS-CoV-2 infections 
by downregulation of ACE2 in high altitude 
acclimatized individuals, at the same time they also 
suggested the positive correlation with hypoxemia 
and related ACE2 upregulation.  
 
Conclusion 
The role of HIF-1α in SARS-CoV-2 infections is 
one of the definitive concern to understand the 
pathogenesis. Although HIF-1α also plays role in the 




pathogenesis of other diseases particularly in patients 
with solid tumours like Head and Neck Squamous 
Cell Carcinoma, Breast Cancers etc., has been 
elucidated in details, the definitive role and crosstalk 
between the HIF-1α mediated pathway and COVID-19 
pathogenesis is yet to be explored. In our opinion 
particularly in context with the cancer patients, where 
the HIF-1α, is a major key player associated with 
tumour biology, the SARS-CoV-2 infection becomes 
more of a concern.  
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